Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is primarily utilized in the development of targeted cancer therapies, particularly in the field of proteolysis-targeting chimeras (PROTACs). Its structure allows it to act as a linker molecule, connecting a target protein-binding moiety (such as pomalidomide) to an E3 ubiquitin ligase-recruiting group. This facilitates the degradation of specific disease-causing proteins, offering a promising approach for treating cancers and other protein-related disorders. Additionally, the PEG2 spacer enhances solubility and bioavailability, while the Boc group provides protection during synthetic processes, ensuring stability and efficiency in drug development.